Effects of Anti-TNF Alpha Drugs on Disability in Patients with Rheumatoid Arthritis: Long-Term Real-Life Data from the Lorhen Registry
Table 3
Patients stratified by their clinical and demographic characteristics. The table shows the number of patients in each subgroup and their mean HAQ scores (except in the case of missing data). The bold indicate that the difference between the subgroups is statistically significant ().
Baseline
6th month
12th month
18th month
24th month
30th month
36th month
42th month
48th month
54th month
60th month
Gender
F; M
847-186
847-186
741-163
660-145
603-136
413-82
529-112
374-81
401-78
303-62
281-63
HAQ
1.47-1.21
1.06-0.75
0-0.96-0.59
0.91-0.56
0.87-0.54
0.8-0.55
0.82-0.5
0.8-0.44
0.81-0.42
0.73-0.43
0.76-0.41
Age
<65; 65; missing
706-245-82
706-245-82
617-218-69
554-193-58
518-172-49
375-106-14
463-142-36
344-97-14
362-107-10
269-84-12
260-76-8
HAQ
1.39-1.62
0.94-1.21
0.81-1.16
0.75-1.15
0.72-1.09
0.68-1.05
0.68-1.08
0.64-1.04
0.67-1.01
0.59-0.96
0.61-0.98
RF
neg; <3x; 3x; missing
75-110-483-365
75-110-483-365
63-104-416-321
55-95-371-284
52-91-327-269
32-57-181-225
47-84-276-234
34-51-165-205
29-56-198-196
24-43-138-160
22-39-139-144
HAQ
1.19-1.2-1.31
0.82-0.89-0.96
0.76-0.75-0.88
0.71-0.73-0.84
0.7-0.7-0.82
0.55-0.62-0.75
0.62-0.68-0.79
0.62-0.56-0.76
0.58-0.56-0.78
0.56-0.49-0.72
0.64-0.54-0.71
Disease duration (years)
<3; 3-5;5-10; 10-15; 15
412-105-181-140-179-16
412-105-181-140-179-16
367-94-150-122-158-13
331-77-131-114-139-13
294-69-120-105-138-13
190-50-88-69-89-9
249-62-108-94-115-13
170-45-76-69-85-10
175-44-81-74-96-9
140-30-59-54-73-9
128-28-52-55-74-7
HAQ
1.23-1.36-1.44-1.64-1.74
0.96-0.8-0.86-1.12-1.3
0.8-0.75-0.76-1-1.24
0.75-0.72-0.68-1-1.21
0.69-0.69-0.72-0.89-1.13
0.63-0.68-0.67-0.85-1.11
0.64-0.67-0.67-0.9-1.08
0.65-0.65-0.59-0.78-1.03
0.62-0.71-0.66-0.86-0.99
0.6-0.68-0.62-0.7-0.86
0.56-0.61-0.58-0.83-0.93
Comorbidity
1; 2; 3; 4; missing
380-188-86-50-329
380-188-86-50-329
335-163-78-45-283
305-146-67-41-246
284-128-62-38-227
190-92-42-30-141
249-114-50-34-194
166-94-39-29-127
177-98-44-27-133
131-80-34-20-100
129-73-32-20-90
HAQ
1.42-1.53-1.64-1.68
1-1.14-1.28-1.08
0.84-1.04-1.2-1.18
0.81-0.95-1.16-1.19
0.8-0.85-1.16-1.01
0.7-0.86-1.24-1.23
0.76-0.83-1-0.99
0.69-0.76-1.21-1.08
0.77-0.75-1.07-1.11
0.66-0.7-0.92-1.2
0.65-0.84-0.86-1.14
Baseline HAQ score
<0.5; 0.5-1; 1-2; 2; missing
53-161-599-205-15
53-161-599-205-15
46-139-532-174-13
40-118-490-143-14
38-108-444-135-14
23-65-310-88-9
34-86-389-118-14
25-50-293-77-10
25-58-286-98-12
21-40-231-64-9
21-37-208-69-9
HAQ
0.48-0.79-1.37-2.35
0.3-0.56-0.99-1.61
0.31-0.5-0.85-1.52
0.25-0.5-0.81-1.44
0.29-0.47-0.77-1.35
0.14-0.46-0.71-1.33
0.15-0.5-0.71-1.32
0.14-0.47-0.71-1.17
0.15-0.43-0.69-1.23
0.14-0.51-0.64-1.1
0.14-0.43-0.63-1.15
Baseline DAS28
<3.2; 3.2-5.1; 5.1; missing
30-218-773-12
30-218-773-12
29-194-671-10
26-161-607-11
21-160-547-11
11-105-370-9
18-135-477-11
12-98-335-10
17-99-354-9
13-73-272-7
15-65-258-6
HAQ
1.01-1.12-1.54
0.55-0.78-1.1
0.59-0.69-0.97
0.72-0.63-0.92
0.33-0.63-0.88
0.31-0.55-0.84
0.27-0.57-0.84
0.38-0.56-0.8
0.39-0.64-0.8
0.37-0.52-0.74
0.35-0.61-0.74
Anti-TNF drug
ADA; ETA; INF; missing
301-227-494-11
301-227-494-11
260-193-442-9
220-171-404-10
208-153-368-10
159-97-231-8
183-128-320-10
143-84-219-9
133-84-254-8
102-68-188-7
80-57-201-6
HAQ
1.24-1.37-1.57
0.86-0.99-1.1
0.77-0.89-0.97
0.76-0.88-0.89
0.7-0.87-0.84
0.73-0.84-0.75
0.7-0.86-0.77
0.67-0.86-0.72
0.65-0.92-0.74
0.67-0.74-0.66
0.72-0.71-0.67
Steroids
No; yes
166-867
166-867
148-756
132-673
124-615
87-408
107-534
83-372
85-394
68-297
65-279
HAQ
1.29-1.45
0.88-1.03
0.74-0.92
0.72-0.87
0.68-0.83
0.65-0.78
0.65-0.79
0.67-0.75
0.65-0.77
0.64-0.69
0.61-0.71
DMARDs
No; yes
83-950
83-950
68-836
53-752
51-688
38-457
48-593
36-419
38-441
29-336
25-319
HAQ
1.53-1.42
1.05-1
0.97-0.89
0.91-0.84
0.9-0.8
1.11-0.73
0.85-0.76
0.89-0.72
0.97-0.73
0.9-0.66
1-0.67
F: female; M: male; RF: rheumatoid factor; <3x RF: low titre [<3 times the upper normal limit of 42 IU/mL]; HAQ: Health Assessment Questionnaire; DAS28: disease activity score in 28 joints; TNF: tumour necrosis factor; ADA: adalimumab; ETA: etanercept; INFL: infliximab; DMARDs: disease modifying antirheumatic drugs.
